EUVIMEDEUVIMED entdecken
Multizentrische Studie

A Multicenter Real‐World Study of Outcomes in Patients With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma Treated With a Polatuzumab Vedotin‐Based Regimen in a Compassionate Use Program in Malaysia

S Fadilah Abdul Wahid iD, Nor Asiah Muhamad, Nor Azimah Ismail, Izzah Athirah Rosli, Chiang Su Kien, Soo Min Lim, Lee Ping Chew, Kirubamoorthy Kamini, Veena Selvaratnam, Ahlam Naila Kori, Teh Hiok Seng, Soo-Chin Ng

Asia-Pacific Journal of Clinical Oncology · 2026

DOI: 10.1111/ajco.14208 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2026. Verfasst von S Fadilah Abdul Wahid und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pusat Terapi Sel (PTS), Hospital Canselor Tuanku Muhriz Universiti Kebangsaan Malaysia (HCTM UKM), Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols, Immunoconjugates, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Roche (Malaysia) Sdn Bhd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Polatuzumab vedotin + bendamustine + rituximab (Pola‐BR) was recently approved in Malaysia for treating relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). A multicenter retrospective study was conducted to assess the effectiveness of this regimen among patients in a compassionate use program.

Objective

To determine treatment response and survival rates for R/R DLBCL patients treated with Pola‐BR in Malaysia. Methodology Safety and efficacy data of 23 adults with R/R DLBCL treated with Pola‐BR at nine centers in Malaysia (September 2019–February 2021) were used. Of the 23 patients, 13 received six cycles of Pola‐BR. The median follow‐up was 10 months (1–37 months). The primary endpoint was complete response (CR) rate; secondary endpoints were overall survival (OS), progression‐free survival (PFS), and adverse events (AEs).

Results

The overall response rate was 56.5%, with 34.8% achieving CR. The 1‐, 2‐, and 3‐year OS rates were 51.6%, 51.6%, and 44.2%, respectively, with a median OS of 27 months. The 1‐ and 2‐year PFS rates were 48.2% and 41.3%, respectively, with a median PFS of 10 months; 60% of the nonresponders had progressive disease. Cox proportional hazard regression analysis showed that bulky disease was a significant hazard for disease progression. A total of 42 AEs were recorded, of which 66.7% were grade ≥ 3 AEs; 90.5% of the AEs were hematological and resolved with treatment; only one patient succumbed to neutropenic sepsis.

Conclusions

Pola‐BR has a favorable safety profile for R/R DLBCL treatment in Malaysia, although larger sample sizes and longer follow‐ups are needed to confirm these results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsImmunoconjugatesNeoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedMalaysiaRetrospective StudiesAdultAgedCompassionate Use TrialsRituximabTreatment OutcomeAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal

Stichwörter der Autor:innen

bendamustinecompassionate use programdiffuse large B‐cell lymphomapolatuzumab vedotinrelapsed/refractory

Substanzen

polatuzumab vedotinImmunoconjugatesRituximabAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal

Autor:innen und Institutionen

  • Pusat Terapi Sel (PTS), Hospital Canselor Tuanku Muhriz Universiti Kebangsaan Malaysia (HCTM UKM), Kuala Lumpur, Malaysia.
  • Sector for Evidence-based Healthcare, National Institutes of Health, Ministry of Health Malaysia, Putrajaya, Malaysia.
  • Department of Medicine, Haematology Unit, Hospital Pulau Pinang, Penang, Malaysia.
  • Department of Haematology, Hospital Sultanah Aminah, Johor Bahru, Johor, Malaysia.
  • Haematology Unit, Medical Department, Sarawak General Hospital, Kuching, Sarawak, Malaysia.
  • Hospital Raja Permaisuri Bainun, Ipoh, Perak, Malaysia.

ORCID-Profile: S Fadilah Abdul Wahid

Förderung

  • Roche (Malaysia) Sdn Bhd

Zitieren

APA

Wahid, S. F. A., Muhamad, N. A., Ismail, N. A., Rosli, I. A., Kien, C. S., Lim, S. M., Chew, L. P., Kamini, K., Selvaratnam, V., Kori, A. N., Seng, T. H., & Ng, S. C. (2026). A Multicenter Real‐World Study of Outcomes in Patients With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma Treated With a Polatuzumab Vedotin‐Based Regimen in a Compassionate Use Program in Malaysia. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.14208

Vancouver

Wahid SFA, Muhamad NA, Ismail NA, Rosli IA, Kien CS, Lim SM, et al. A Multicenter Real‐World Study of Outcomes in Patients With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma Treated With a Polatuzumab Vedotin‐Based Regimen in a Compassionate Use Program in Malaysia. Asia-Pacific Journal of Clinical Oncology. 2026. doi:10.1111/ajco.14208

BibTeX
@article{Wahid2026,
  author = {Wahid, S Fadilah Abdul and Muhamad, Nor Asiah and Ismail, Nor Azimah and Rosli, Izzah Athirah and Kien, Chiang Su and Lim, Soo Min and Chew, Lee Ping and Kamini, Kirubamoorthy and Selvaratnam, Veena and Kori, Ahlam Naila and Seng, Teh Hiok and Ng, Soo-Chin},
  title = {A Multicenter Real‐World Study of Outcomes in Patients With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma Treated With a Polatuzumab Vedotin‐Based Regimen in a Compassionate Use Program in Malaysia},
  journal = {Asia-Pacific Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1111/ajco.14208}
}
Kostenlos starten →